Consolidated PAT surges ~6.9x YoY to ₹33.7 Cr on 90% revenue growth; margin eases QoQ
PAT +593.3% YoY · revenue +89.7% · margins expanding
₹347.68 Cr
+89.7% YoY
₹33.68 Cr
+593.3% YoY
9.68%
+7pp YoY
₹27.93
Yasho Industries' consolidated PAT came in at ₹33.68 Cr for Q2 FY27, up ~5.9x YoY from ₹4.86 Cr, on consolidated revenue of ₹347.68 Cr, up 89.7% YoY from ₹183.30 Cr — a continuation of the volume-led ramp the company flagged on its Q1 call (42% volume growth, better capacity utilisation, favorable mix). No reliable street/consensus estimate for this specific quarter could be sourced, so the print is assessed against the company's own guidance rather than a street number. Standalone PAT grew even faster YoY (+968%, ₹2.87 Cr to ₹30.65 Cr) than consolidated (+593%) because the year-ago quarter's subsidiary contribution was proportionally larger than this quarter's — the headline consolidated number is the more complete read, but readers comparing to standalone should expect a steeper YoY jump there.
Q2 FY-2027 vs prior quarters
Sequentially, growth continued (revenue +13.0% QoQ versus Q1 FY27's ₹307.74 Cr) but profitability eased: PAT fell 6.6% QoQ from Q1's record ₹36.05 Cr, and OPM (EBITDA/revenue) slipped to 20.90% from 23.75% in Q1 (reported as 24.2% EBITDA margin on the Q1 call). NPM still expanded sharply YoY, from 2.65% to 9.69%, so the YoY margin story remains one of expansion — the QoQ dip reads as normalization off an unusually strong Q1 base rather than a deterioration, since this is a specialty-chemicals business with no obvious seasonal driver.
The stock went into the print at ₹3,343, down 21% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
EPS (basic, consolidated) ₹27.93 for the quarter vs ₹4.03 a year ago and ₹29.90 last quarter.
No exceptional items in either the current or year-ago quarter — growth is entirely operational, not one-off driven.
FY28 revenue >₹1,600 Cr (raised from ₹1,500 Cr). Endeavor to maintain 24% EBITDA margin going forward. FY27 CAPEX ₹250 Cr (raised from ₹125 Cr) for two production buildings at Pakhajan. Targeting 30-40% annual revenue growth next few years backed by marquee customer long-term contracts.
— This quarter: met
On guidance: revenue growth of 90% YoY is far ahead of management's targeted 30-40% annual growth band, a clear beat on that front. Capex execution also tracks the raised FY27 target of ₹250 Cr for the two Pakhajan production buildings — ₹131.29 Cr was already deployed in H1 FY27 (capital work-in-progress rose from ₹10.04 Cr at FY26-end to ₹131.05 Cr), roughly half the full-year budget spent in the first half. The one guidance metric this quarter missed is margin: management's stated endeavor to maintain ~24% EBITDA margin wasn't met, with OPM at 20.90% versus Q1's 24.2%. No management press release was available for this result to cross-check commentary against the print, and the quarter's corporate-action record shows only the standard results-cycle events (trading window closure, board meeting notice) — no incremental deal or capacity announcements beyond the ongoing Pakhajan capex already reflected in the balance sheet.
W1
Whether OPM recovers toward management's ~24% EBITDA margin endeavor in Q3 FY27 after easing to 20.90% this quarter.
W2
Pace of the remaining Pakhajan capex (₹131 Cr of the ₹250 Cr FY27 budget already spent) and its effect on depreciation/finance costs as the two new buildings come online.
W3
Whether revenue growth holds near management's 30-40% annual growth target — H1 FY27 revenue of ₹655.42 Cr is already running well ahead of that band YoY.
No exceptional items in current or year-ago quarter; consolidated covers two wholly-owned subs (Yasho Industries Europe B.V., Yasho Inc), no NCI line; clean digital PDF, unambiguous column headers, both self-checks passed.
Strong growth masked by margin compression and cost headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met H1 growth expectations (89.7% YoY vs 71.7% claimed). Reaffirmed FY28 >₹1,600 Cr (raised prior ₹1,500 Cr). But cut EBITDA margin aspiration (24% → 20-21%).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue momentum (90% YoY) backed by 62% volume growth and new capacity. But Q2 delivered margin compression (300 bps QoQ), QoQ PAT decline of 6.6%, and management downgraded EBITDA aspiration from 24% to 20-21%. Freight and energy cost headwinds unresolved; analyst pressure on how 66% utilization coexists with 40% growth suggests execution stress. Long-term contract and capex expansion are credible catalysts, but near-term execution risk is material.
₹347.7 Cr
Revenue · +89.7% YoY₹33.7 Cr
Reported PAT · +593.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
62% volume growth YoY, 7% QoQ
METRevenue growth 89.7% YoY, 13% QoQ implies ~17% pricing contribution YoY
Capacity utilization 66% in Q2, up from 60% in Q4 FY26
METNo conflicting data; context shows 6ppt growth in utilization despite 40% revenue growth (suggests product mix shift, new customer onboarding capacity constraints)
Maintain 24% EBITDA margin going forward
MISSManagement now targets 20%-21% EBITDA margin, explicit downgrade under cost pressure
Export 70% of revenue in Q2 FY27
METManagement confirmed in Q&A: Q1 FY27 ~65%, Q2 FY27 ~70%
Freight cost impact ₹20 Cr in Q2 vs ₹10 Cr in Q1
METDisclosed in CFO remarks; additional headwind of ₹1.8 Cr from gas prices
Earnings quality
What changed since the last call
EBITDA margin aspiration downgraded
DowngradePrior 'maintain 24% EBITDA margin'; now 'target 20%-21% or more than that, but that's our aspiration'. Cost headwinds (freight ₹20 Cr Q2, energy, logistics delays) and new product ramp-up margin dilution cited as drivers.
FY27 capex raised
Upgrade₹125 Cr (prior) → ₹250 Cr (now) for two Pakhajan manufacturing buildings. Incremental commitment reflects customer demand and long-term contract expectations.
FY28 revenue guidance reaffirmed
Neutral>₹1,600 Cr (no change from Q1 call). Management reaffirms but hedges further: 'We are positive even today, but I don't want to commit anything more. Very clear, it will be more than 1,600.'
New long-term customer contract disclosed
NewMNC supply agreement ₹150 Crores order book; ₹120 Cr received to date; trial Q4 FY27, commercialization Q1 FY28. Expected to contribute multi-year growth.
The Q&A
Analysts pressed hard on capacity utilization lag (only 66% despite 40% growth target), margin compression (300 bps Q-o-Q), cost pass-through inability, and EBITDA margin downgrade. Management held but hedged heavily: acknowledged cost challenges are 'temporary', reaffirmed '>₹1,600 Cr' but without precision, refused to commit to 24% EBITDA ('too difficult in current situation'). Q&A revealed caution, not confidence.
Revenue growth vs utilization mismatch — Lovish Soien, Burman Capital Management
PartialVolume 7% QoQ, utilization Q4 to Q2 from 60% to 66%. Pricing up 10-15%. Product mix shift to new higher-margin products. New customer onboarding absorbed extra capacity. Explains utilization lag.
MNC contract scope and materiality — Aman Vij, Asutec Investment Management
DodgedNDA prevents customer name disclosure. Multiple products involved. 'One of the big MNC, you're talking about other four, I don't know about other four.' Cannot divert information.
EBITDA margin maintenance — Umesh Gupta, AlphaOptimus PMS
Answered20% will be lower side. Anything above that could be guess. Margin shrunk due to freight and energy. 'I cannot assure that we will achieve 24% or I will achieve 25%.' Too difficult in current situation. Aspiring to go down — passing benefit to customer.
Margin decline drivers — Darshil Jhaveri, Crown Capital
PartialWorking hard to maintain margin. Demand growing. Reaching existing and new customers with pricing band. In short term, no challenge. Export market raw material costs volatile. Need caution on cost pass-through.
Phase 2 capex and customer-backed utilization — Lovish Soien, Burman Capital Management
AnsweredSoft commitment from customer. About 50% of total utilization. Mix of existing and new customers onboarded. Confidence to put capex based on existing order visibility.
Export market opportunity and localization strategy — Lovish Soien, Burman Capital Management
AnsweredYes, inquiries on localization. 'Sizeable opportunity.' Local Indian product sourced. Part of the growth strategy, part of the ₹250 Crores incremental, not all.
FY28 revenue guidance conservatism — Kanav Garg, Garg Advisors
PartialBetter to be conservative than optimistic. Will be happy if cross target. If don't cross, will ask what went wrong. '>₹1,600 Cr' without absolute commitment. Very clear, it will be more than 1,600.
Business model diversification and customization — Gulam Soni, Individual Investor
PartialR&D team works on different projects including lubricant and other industrial applications. Focus will be leveraging chemistry expertise. Beyond FY28 targeting ₹1,600 Crores. Further strategy given at end-27 call.
Guidance
FY28 revenue >₹1,600 Crores
MediumReaffirmed from Q1 call (prior ₹1,500 Cr). Backed by ₹150 Cr MNC contract (trial Q4 FY27, launch Q1 FY28) and capex expansion. But >₹1,600 is vague, not a specific target. Management hedged: 'Very clear, it will be more than 1,600.'
EBITDA margin 20%-21% (down from 24% prior)
LowManagement says '20% will be the lower side.' But cannot commit to 24% or higher. Cost headwinds (freight, energy, logistics delays) cited. Aspirational target, not committed.
FY27 capex ₹250 Crores (raised from ₹125 Cr)
HighTwo manufacturing buildings at Pakhajan. Building 1 & 2 to ramp H2 FY27 / Q1 FY28. Building 3 & 4 operational by Q4 FY28 / Q1 FY29. Partially funded by equipment for existing buildings.
Risks the call surfaced
Margin compression durability
HighFreight costs doubled to ₹20 Cr in Q2; energy/gas costs ₹1.8 Cr; management unable to pass through 100% of cost increases due to fixed contract constraints. Q2 PAT -6.6% QoQ despite 13% revenue growth signals pricing power limits.
Capacity utilization lag
MediumQ2 utilization 66% despite 40% revenue growth implies efficiency loss. Explained by product mix shift, new customer onboarding, and SKU expansion (140 → 152 products). Phase 1 building expected 80-85% utilization by FY29; Phase 2 at 50-60% Y1 startup. Risk of prolonged low utilization and ROI delay.
Export logistics and geopolitical risk
MediumExport revenue 70% of Q2 (up from 63% FY26). Logistics delays 30-60 days vs historical 25-30 days. Geopolitical sanctions on Chinese chemical players benefit Yasho, but duration uncertain. Shipping costs volatile; fuel surcharges unpredictable.
Customer concentration (unnamed MNC)
Medium₹150 Crores order book from unnamed MNC (NDA prevents disclosure). 15-year agreement provides duration, but customer concentration risk exists. Trial production Q4 FY27, commercialization Q1 FY28 — execution risk if trial fails.
Raw material price volatility and sourcing
Low10-15% raw material price increase in Q2 (March to September). Analyst noted 'unavailability of raw material because of the crisis.' Management says 'lot of challenges currently to procure the raw material, but that's okay. That's part of personal life.' Pricing power may not sustain if sourcing gets tighter.
Management
Score 6/10. Transparent on headwinds (freight, energy costs, logistics delays) but evasive on MNC contract scope due to NDA. Hedged on FY28 guidance ('>₹1,600 Cr' not a firm number). Downgraded EBITDA margin aspiration but acknowledged in Q&A. Met H1 growth expectations (89.7% YoY). Reaffirmed FY28 >₹1,600 Cr (raised from ₹1,500 Cr). Capex raised ₹125 Cr → ₹250 Cr, on track. But margin aspiration cut from 24% to 20-21%, signaling execution pressure.
1 · Q4 FY27
MNC contract trial production start; Pakhajan Phase 1 building commissioning outlook
2 · Q1 FY28
MNC contract commercialization (₹150 Cr order book); Phase 1 operations ramp
3 · H2 FY28+
Phase 2 building operational at 50-60% utilization; targeted 30-40% annual revenue growth; FY28 >₹1,600 Cr achievement
Long-term contract and capex expansion are credible catalysts, but near-term execution risk is material.
Growth Momentum, Earnings Headwind: The Margin Downgrade Story
Revenue surged 89.7%, but profit contracted 6.6% quarter-on-quarter and management cut EBITDA margin guidance from 24% to 20–21%. The growth is real—but the quarter revealed cost durability, not pricing power.
₹33.7 Cr
+593% YoY
−6.6%
despite +13% revenue
₹20 Cr
vs ₹10 Cr Q1 (doubled)
20–21%
down from 24% prior
The headline number hides the real story
Yasho's Q2 delivered ₹347.7 Cr in revenue, up a legitimate 89.7% year-on-year. But the reported profit of ₹33.7 Cr fell 6.6% quarter-on-quarter, even as sales climbed 13%. The call reveals why: freight costs doubled from ₹10 Cr to ₹20 Cr, energy prices spiked ₹1.8 Cr additional, and management cannot pass through the full hit to existing fixed-contract customers. The company raised FY-2027 capex from ₹125 Cr to ₹250 Cr and disclosed a ₹150 Cr long-term MNC supply deal—genuine positive catalysts. But it also cut EBITDA margin guidance from a stated 24% aspiration to 20–21%, signalling that cost pressures are durability, not transient.
62% volume growth YoY, 7% QoQ — Supported by revenue bridge (89.7% YoY with ~17% pricing contribution)
Export revenue 70% of Q2, up from 63% FY26 — Confirmed in Q&A by management
Capacity utilization 66% in Q2, up from 60% Q4 FY26 — Supported; explained by product mix shift and new customer onboarding
Maintain 24% EBITDA margin going forward — Contradicted; management now targets 20–21%
Freight cost ₹20 Cr in Q2 vs ₹10 Cr Q1 — Explicitly disclosed by CFO
₹150 Cr MNC supply contract (15-year agreement) — Supported; ₹120 Cr received to date, trial Q4 FY27
What changed on this call
EBITDA margin aspiration
Maintain 24%Target 20–21%
Downgrade — cost headwinds deemed durable
FY27 capex (Pakhajan buildings)
₹125 Cr₹250 Cr
Upgrade — customer demand validation, 15-year MNC contract
FY28 revenue guidance
>₹1,600 Cr>₹1,600 Cr (held)
Neutral — no change from Q1; management hedged ('don't want to commit anything more')
Long-term supply contract
Not disclosed₹150 Cr MNC order book, 15-year term
New catalyst — de-risks revenue stream, materializes capex thesis
The cost of freight increased from INR 10 crores in Q1 to INR 20 crores in Q2. Increase in gas prices in the quarter also resulted in an additional expenditure of INR 1.8 crores.
I cannot assure that we will achieve 24% or I will achieve 25%. Too difficult to say in the current situation.
The bull-bear ledger
Genuine volume growth momentum: 62% YoY volume gain on strong customer demand
Long-term contract de-risks revenue: ₹150 Cr MNC deal over 15 years; ₹120 Cr already received
Capex commitment signals confidence: ₹250 Cr for two Pakhajan buildings backed by customer soft-commitments
Pricing power demonstrated: 10–15% price realisation increase in Q2 on strong positioning
Export tailwind from geopolitical shift: Chinese chemical player sanctions drive localization demand
QoQ profit decline despite revenue growth: ₹33.7 Cr (−6.6% QoQ) signals cost not yet under control
EBITDA margin guidance slashed: Downgrade from 24% to 20–21% contradicts prior confidence
Freight cost pass-through incomplete: Fixed-contract customers cap pricing power; ₹20 Cr freight headwind unresolved
Utilization lag vs. growth: 66% utilization despite 40% growth target; Phase 2 ramp-up timing uncertain (50–60% Y1 from FY28)
Export revenue concentration: 70% of Q2 revenue; logistics delays (30–60 days vs. 25–30 day standard) material headwind
Customer concentration masked by NDA: Unnamed MNC is material (₹150 Cr of ₹1,600 Cr FY28 target = ~9%)
Risks, ranked by severity for a holder
Margin compression durability
HighFreight doubled Q-o-Q (₹10 Cr → ₹20 Cr), energy spiked ₹1.8 Cr, management cut EBITDA guidance from 24% to 20–21%. This signals cost pressures are structural (logistics delays 30–60 days persist), not transient. Fixed-contract customers prevent 100% pricing pass-through. Risk: EBITDA margin stays depressed even as volume ramps, compressing ROI on ₹250 Cr capex.
Capacity utilization lag vs. revenue growth
MediumQ2 utilization 66% despite 40% annual revenue growth target. Product mix shift and new customer onboarding explained it, but Phase 1 building expected only 80–85% utilization by FY29 and Phase 2 at 50–60% Y1 startup. Risk: capex ROI delayed or lower-than-modelled if ramp slower. Return on ₹250 Cr spend pushed beyond FY28.
Export logistics and geopolitical volatility
Medium70% of Q2 revenue is export-dependent. Current shipping delays 30–60 days (vs. 25–30 day normal), freight volatile. Geopolitical sanctions on Chinese players are tailwind now, but if they normalize (Chinese players re-enter), competitive pressure rises. Risk: export margins compressed or volume loss.
Customer concentration (unnamed MNC)
Medium₹150 Cr MNC supply contract (15-year, 15% of FY28 ₹1,600 Cr target) is material, but NDA prevents disclosure of customer name or product scope. Trial Q4 FY27, launch Q1 FY28 — execution risk if trial fails. Risk: single-customer loss or ramp delay could miss FY28 guidance.
Raw material and energy price volatility
Low-Medium10–15% raw material price increase in Q2; energy cost spiked ₹1.8 Cr. Analyst noted 'unavailability of raw material because of crisis.' Sourcing tightness may persist. Risk: if pricing power erodes further or sourcing breaks, margin outlook worsens.
How the street is positioned
Valuation and drawdown context: The stock trades at ₹3,279.5, down 34.3% from its all-time high of ₹4,990, and is trading below its 20-day (₹3,744) and 50-day (₹3,971) moving averages, though above its 200-day average (₹2,595). This suggests a correction in growth/valuation expectations post-ATH, but the stock remains up 190% off its 52-week low of ₹1,130. The drawdown reflects market skepticism on margin durability and utilization execution, not fundamentals collapse.
Institutional positioning: FII ownership stands at 5.74% (latest Q1 FY27 filing), up marginally from 5.71% in Q4 FY26. DII holdings are 2.21%, up from 1.97% Q4 FY26. Promoter stake remains steady at 67.94%. The flat-to-modest FII inflow and DII pickup suggest cautious institutional interest despite the margin headwinds; insiders are not selling. This is consistent with a 'prove-it' posture — the street wants to see margin recovery and capex ROI before recommitting.
The street's verdict: The 34% drawdown from ATH, combined with neutral-to-cautious Q&A sentiment (analysts pressed hard on utilization lag, margin guidance cut, and cost pass-through limits), signals the market has repriced growth downward. But the mild FII accumulation and stable insider holding suggest conviction remains on the long-term thesis (capex, MNC contract, export tailwind). The stock's current valuation reflects a 'show-me' moment: margin recovery and Phase 1 capex deployment will determine whether the drawdown was overblown or prescient.
The debate
What to watch next
1 · Freight cost stabilization and logistics delays recovery
Q2 freight doubled to ₹20 Cr; logistics delays running 30–60 days vs. 25–30 day normal. If Q3 freight returns to ₹12–₹15 Cr range and shipping normalizes to 25–30 days, margin recovery toward 22–23% is credible. If freight stays ≥₹18 Cr and delays persist, management's 20–21% aspiration becomes the ceiling, not a floor. Track CFO commentary on freight outlook in Q3 results and call.
2 · MNC contract trial production milestone (target Q4 FY27)
₹150 Cr MNC supply deal (15-year, ₹120 Cr received to date) trial production starts Q4 FY27, commercialization Q1 FY28. If trial succeeds and Phase 1 building ramps on schedule, this is the catalyst for FY28 >₹1,600 Cr achievement. If trial slips or commercialization delays, capex payback and FY28 guidance become at-risk. Watch for management commentary on trial progress in Q3 call.
3 · Phase 1 building capacity utilization trend (Q3–Q4 FY27)
Q2 utilization 66%; target 75% by FY27 end, then 80–85% by FY29. If utilization climbs to 70%+ by Q3 and stays there through Q4, margin recovery thesis gains credibility. If utilization stalls below 68%, the 'ramp execution risk' becomes real, and Phase 2 capex ROI falls into question. Track quarterly utilization disclosures and management tone on new customer onboarding success.
The single number to track from here
Operating profit margin (OPM) in Q3 and Q4 FY27. Q2 OPM is 20.9%; management guidance is EBITDA 20–21%. If Q3 OPM stays ≥20.5%, the margin floor is holding and recovery is plausible. If Q3 OPM falls to ₹1,600 Cr revenue target translates to earnings growth or earnings stagnation.
Yasho Industries delivered genuine growth — 89.7% revenue, 62% volume gain, real customer demand, a long-term contract, and capex commitment. But the quarter also proved that cost inflation (freight, energy) is eating earnings faster than pricing can offset it. Management's EBITDA margin downgrade from 24% to 20–21% is the tell: they are not confident on recovery in the near term. The stock's 34% drawdown from ATH reflects this repricing correctly. The next leg of returns depends not on revenue growth — that's proven — but on margin recovery. If freight normalizes and Phase 1 utilization ramps, the stock could re-rate toward ₹4,000+. If costs stay elevated and utilization lags, the stock stays ranged ₹2,600–₹3,800. For a holder, the answer lies in Q3 and Q4 operating profit. For a prospective buyer, the 34% correction offers entry near fair value on a 20–21% EBITDA margin base — but not upside, until margins prove.